Search

Your search keyword '"Tu, Janet"' showing total 470 results

Search Constraints

Start Over You searched for: Author "Tu, Janet" Remove constraint Author: "Tu, Janet"
470 results on '"Tu, Janet"'

Search Results

1. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

5. Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients

8. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial).

9. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

10. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA

12. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

13. Abstract C084: iExplore: A phase I study of mesenchymal stem cell derived exosomes with KrasG12D siRNA for metastatic pancreas cancer patients harboring the KrasG12D mutation

15. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer

16. Abstract 4393: Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC

18. Abstract LB001: Identifying MAGE-A4-positive tumors for SPEAR T-cell therapies in HLA-A*02-eligible patients

19. Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant, EGFR-mutant non–small cell lung cancer (NSCLC).

20. Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study.

21. Brief Report: Longitudinal tracking of ALKrearranged non-small cell lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA

23. Evaluation and Improvement of Bottlenecking in a Multidisciplinary Oncology Clinic: An Electronic Medical Record Intervention

24. The boiling point

25. What's at stake with Windows 9?

26. The Mainstream and Beyond

27. Longitudinal tracking of ALK -positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial.

28. Not all Jews in Seattle want public menorah; Airport controversy stirs debate

31. AJC fills director's seat

38. Giant sacrifice for a little prince and his family

Catalog

Books, media, physical & digital resources